The use of hormone replacement therapy in postmenopausal women with type 2 diabetes

Journal of Women's Health and Gender-Based Medicine

Volumn 10, Issue 3, 2001, Pages 241-255

  Cefalu, William T ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ANDROGEN; APOLIPOPROTEIN A; APOLIPOPROTEIN B; C PEPTIDE; C REACTIVE PROTEIN; CARBOHYDRATE; CHOLESTEROL; CONJUGATED ESTROGEN; DIHYDROEQUILIN; EQUILIN SULFATE; ESTRADIOL; ESTROGEN DERIVATIVE; ESTRONE SULFATE; GESTAGEN; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HORMONE BINDING PROTEIN; INSULIN; LEVONORGESTREL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE ACETATE; PLACEBO; PROGESTERONE DERIVATIVE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BREAST CANCER; CARBOHYDRATE METABOLISM; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG FORMULATION; DRUG METABOLISM; ENDOMETRIUM CANCER; FEMALE; GALLBLADDER DISEASE; GLUCOSE INTOLERANCE; HORMONE SUBSTITUTION; HUMAN; INSULIN RESISTANCE; LIPID METABOLISM; MALE; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PARAMETER; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SYMPTOM; THROMBOEMBOLISM;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DRUG MONITORING; ESTROGEN REPLACEMENT THERAPY; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; OSTEOPOROSIS, POSTMENOPAUSAL; PATIENT SELECTION; POSTMENOPAUSE; RISK FACTORS; TREATMENT OUTCOME; WOMEN'S HEALTH;

EID: 0035022462     PISSN: 15246094     EISSN: None     Source Type: Journal    
DOI: 10.1089/152460901300139998     Document Type: Review

References (146)

1. Spencer CP, Godsland IF, Stevenson JC. Is there a menopausal metabolic syndrome? Gynecol Endocrinol 1997;11:341.
2. Walton C, Godsland IF, Proudler AJ, Wynn V, Stevenson JC. The effects of the menopause on insulin sensitivity, secretion and elimination in non-obese, healthy women. Eur J Clin Invest 1993;23:466.
3. Godsland IF, Walton C, Stevenson JC. Impact of menopause on metabolism. In: Diamond MP, Naftolin F, eds. Metabolism in the female cycle. Rome, Italy: Ares-Serono Symposia Publications, 1993:171.
4. Writing group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995;273:199.
5. Adami S, Rossini M. Zamberlan N, Bertoldo F, Dorizzi R, Lo Cascio V. Long-term effects of transdermal and oral estrogens on serum lipids and lipoproteins in postmenopausal women. Maturitas 1993;17:191.
6. Lindsay R, Aitken JM, Anderson JB, Hart DM, MacDonald EB, Clarke AC. Long-term prevention of postmenopausal osteoporosis by oestrogen: Evidence for an increased bone mass after delayed onset of oestrogen treatment. Lancet 1976;1:1038.
7. Ettinger B, Genant HK, Cann CE. Long-term estrogen replacement therapy prevents bone loss and fractures. Ann Intern Med 1985;102:319.
8. Wilcox JG, Hwang J, Hodis HN, Sevanian A, Stanczyk FZ, Lobo RA. Cardioprotective effects of individual conjugated equine estrogens through their possible modulation of insulin resistance and oxidation of low-density lipoprotein. Fertil Steril 1997;67:57.
9. Lobo RA, Pickar JH, Wild RA, Walsh B, Hirvonen E. Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women. Obstet Gynecol 1994;84:987.
10. Espeland MA, Hogan PE, Fineberg SE, et al. Effect of postmenopausal hormone therapy on glucose and insulin concentrations. Diabetes Care 1998;21:1589.
11. Raudaskoski T, Tomas C, Laatikainen T. Insulin sensitivity during postmenopausal hormone replacement with transdermal estradiol and intrauterine levonorgestrel. Acta Obstet Gynecol Scand 1999;78: 540.
12. Hänggi W, Lippuner K, Jaeger P, Birkhäuser MH, Horber FF. Differential impact of conventional oral or transdermal hormone replacement therapy or tibolone on body composition in postmenopausal women. Clin Endocrinol 1998;48:691.
13. Reubinoff BE, Wurtman J, Rojansky N, et al. Effects of hormone replacement therapy on weight, body composition, fat distribution, and food intake in early postmenopausal women: A prospective study. Fertil Steril 1995;64:963.
14. Gambacciani M, Ciaponi M, Cappagli B, et al. Body weight, body fat distribution, and hormonal replacement therapy in early postmenopausal women. J Clin Endocrinol Metab 1997;82:414.
15. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidence. Prev Med 1991;20:47.
16. Stampfer MJ, Willett WC, Colditz GA, Rosner B, Speizer FE, Hennekens CH. A prospective study of postmenopausal estrogen therapy and coronary heart disease. N Engl J Med 1985;313:1044.
17. Phillips P. Diabetes and the Menopause: Special considerations. Aust Fam Physician 1998;27:59.
18. Edelman SV. Type II diabetes mellitus. Adv Intern Med 1998;43:449.
19. Sowers JR. Diabetes mellitus and cardiovascular disease in women. Arch Intern Med 1998;158:617.
20. Barrett-Connor E, Cohn BA, Wingard DL, Edelstein SL. Why is diabetes mellitus a stronger factor for fatal ischemic heart disease in women than in men? The Rancho Bernardo Study. JAMA 1991;265:627.
21. Feher MD, Isaacs AJ. Is hormone replacement therapy prescribed for postmenopausal diabetic women? Br J Clin Pract 1996;50:431.
22. Keating NL, Cleary PD, Rossi AS, Zaslavsky AM, Ayanian JZ. Use of hormone replacement therapy by postmenopausal women in the United States. Ann Intern Med 1999;130:545.
23. Godsland IF, Crook D, Simpson R, et al. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N Engl J Med 1990;323:1375.
24. Physicians' desk reference. Montvale, NJ: Medical Economics Company, Inc., 1999.
25. Johnson SR. Menopause and hormone replacement therapy. Med Clin North Am 1998;82:297.
26. Reginster JY, Christiansen C, Dequinze B, et al. Effect of transdermal 17β-estradiol and oral conjugated equine estrogens on biochemical parameters of bone resorption in natural menopause. Calcif Tissue Int 1993;53:13.
27. Cauley JA, Seeley DG, Ensrud K, et al. Estrogen replacement therapy and fractures in older women. Ann Intern Med 1995;122:9.
28. Naessén T, Persson I, Adami H-O, Bergström R, Bergkvist L. Hormone replacement therapy and the risk for first hip fracture. Ann Intern Med 1990;113: 95.
29. Meschia M, Bruschi F, Soma M, Amicarelli F, Paoletri R, Crosignani P. Effects of oral and transdermal hormone replacement therapy on lipoprotein(a) and lipids: A randomized controlled trial. Menopause 1998;5:157.
30. Miller VT, Muesing RA, LaRosa JC, Stoy DB, Fowler SE, Stillman RJ. Quantitative and qualitative changes in lipids, lipoproteins, apolipoprotein(a)-I, and sex hormone-binding globulin due to two doses of conjugated equine estrogen with and without a progestin. Obstet Gynecol 1994;83:173.
31. Miller VT, Muesing RA, LaRosa JC, Stoy DB, Phillips EA, Stillman RJ. Effects of conjugated equine estrogen with and without three different progestogens on lipoproteins, high-density lipoprotein subtractions, and apolipoprotein(a)-I. Obstet Gynecol 1991;77:235.
32. O'Sullivan AJ, Crampton LJ, Freund J, Ho KKY. The route of estrogen replacement therapy confers divergent effects on substrate oxidation and body composition in postmenopausal women. J Clin Invest 1998;102:1035.
33. Shwaery GT, Vita JA, Keaney JF Jr. Antioxidant protection of LDL by physiologic concentrations of estrogens is specific for 17-beta-estradiol. Atherosclerosis 1998;138:255.
34. McManus J, McEneny J, Thompson W, Young IS. The effect of hormone replacement therapy on the oxidation of low density lipoprotein in postmenopausal women. Atherosclerosis 1997;135:73.
35. Wren BG, Routledge AD. The effect of type and dose of oestrogen on the blood pressure of postmenopausal women. Maturitas 1983;5:135.
36. Alfie J, Lugones L, Belardo A, et al. Hemodynamic effects of transdermal estradiol alone and combined with norethisterone acetate. Maturitas 1997;27:163.
37. Mercuro G, Zoncu S, Piano D, et al. Estradiol-17β reduces blood pressure and restores the normal amplitude of the circadian blood pressure rhythm in postmenopausal hypertension. Am J Hypertens 1998;11:909.
38. Selzman CH, Whitehill TA, Shames BD, Pulido EJ, Cain BC, Harken AH. The biology of estrogen-mediated repair of cardiovascular injury. Ann Thorac Surg 1998;65:868.
39. Mosca L. Estrogen and atherosclerosis. J Invest Med 1998;46:381.
40. Castellsague J, Pérez Gutthann S, García Rodríguez LA. Recent epidemiological studies of the association between hormone replacement therapy and venous thromboembolism: A review. Drug Safety 1998; 18:117.
41. Sherwin BB. Estrogen and cognitive functioning in women. Proc Soc Exp Biol Med 1998;217:17.
42. Paganini-Hill A, Henderson VW. Estrogen replacement therapy and risk of Alzheimer disease. Arch Intern Med 1996;156:2213.
43. Kawas C, Resnick S, Morrison A, et al. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: The Baltimore Longitudinal Study of Aging. Neurology 1997; 48:1517.
44. Kampman E, Potter JD, Slattery ML, Caan BJ, Edwards S. Hormone replacement therapy, reproductive history, and colon cancer: A multicenter, case-control study in the United States. Cancer Causes Control 1997;8:146.
45. Fernandez E, La Vecchia C, Braga C, et al. Hormone replacement therapy and risk of colon and rectal cancer. Cancer Epidemiol Biomarkers Prev 1998;7:329.
46. Grodstein F, Martinez ME, Platz EA, et al. Postmenopausal hormone use and risk for colorectal cancer. Ann Intern Med 1998;128:705.
47. Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: A meta-analysis. Obstet Gynecol 1995;85:304.
48. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997;350:1047.
49. Grodstein F, Stampfer MJ, Colditz GA, et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997;336:1769.
50. Col NF, Eckman MH, Karas RH, et al. Patient-specific decisions about hormone replacement therapy in postmenopausal women. JAMA 1997;277:1140.
51. Limouzin-Lamothe M-A, Mairon N, Joyce CRB, Le Gal M. Quality of life after the menopause: Influence of hormonal replacement therapy. Am J Obstet Gynecol 1994;170:618.
52. Hilditch JR, Lewis J, Ross AH, et al. A comparison of the effects of oral conjugated equine estrogen and transdermal estradiol-17β combined with an oral progestin on quality of life in postmenopausal women. Maturitas 1996;24:177.
53. Petitti DB, Sidney S, Perlman JA. Increased risk of cholecystectomy in users of supplemental estrogen. Gastroenterology 1988;94:91.
54. Sherwin BB. Estrogen effects on cognition in menopausal women. Neurology 1997;48(Suppl 7):S21.
55. Calle EE, Miracle-McMahill HL, Thun MJ, Health CW Jr. Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women. J Natl Cancer Inst 1995;87:517.
56. Subbiah MTR. Mechanisms of cardioprotection by estrogens. Proc Soc Exp Biol Med 1998;217:23.
57. Lim SC, Caballero AE, Arora S, et al. The effect of hormonal replacement therapy on the vascular reactivity and endothelial function of healthy individuals and individuals with type 2 diabetes. J Clin Endocrinol Metab 1999;84:4159.
58. Kawano H, Motoyama T, Kugiyama K, et al. Gender difference in improvement of endothelium-dependent vasodilation after estrogen supplementation. J Am Coll Cardiol 1997;30:914.
59. Bush DE, Jones CE, BAss KM, Walters GK, Bruza JM, Ouyang P. Estrogen replacement reverses endothelial dysfunction in postmenopausal women. Am J Med 1998;104:552.
60. Xu R, Morales JA, Muniyappa R, Skafar DF, Ram JL, Sowers JR. Interleukin-1beta-induced nitric oxide production in rat aortic endothelial cells: Inhibition by estradiol in normal and high glucose cultures. Life Sci 1999;64:2451.
61. Meyer MC, Cummings K, Osol G. Estrogen replacement attenuates resistance artery adrenergic sensitivity via endothelial vasodilators. Am J Physiol 1997; 272:H2264.
62. Cauley JA, Cummings SR, Black DM, Mascioli SR, Seeley DG. Prevalence and determinants of estrogen replacement therapy in elderly women. Am J Obstet Gynecol 1990;163:1438.
63. Kessel B. Alternatives to estrogen for menopausal women. Proc Soc Exp Biol Med 1998;217:38.
64. Pilote L, Hlatky M. Attitudes of women toward hormone therapy and prevention of heart disease. Am Heart J 1995;129:1237.
65. Taylor M. Alternatives to conventional hormone replacement therapy. Compr Ther 1997;23:514.
66. Creasman WT. Is there an association between hormone replacement therapy and breast cancer? J Womens Health 1998;7:1231.
67. Braendle W. Hormone replacement therapy in women with breast cancer. Anticancer Res 1999;18: 2253.
68. Bunker JP, Houghton J, Baum M. Putting the risk of breast cancer in perspective. Br Med J 1998;317:1307.
69. Persson I, Adami H-O, Bergkvist L, et al. Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: Results of a prospective study. Br Med J 1989;298:147.
70. Brinton LA, Hoover RN, and the Endometrial Cancer Collaborative Group. Estrogen replacement therapy and endometrial cancer risk: Unresolved issues. Obstet Gynecol 1993;81:265.
71. Pickar JH, Thorneycroft I, Whitehead M. Effects of hormone replacement therapy on the endometrium and lipid parameters: A review of randomized clinical trials, 1985 to 1995. Am J Obstet Gynecol 1998; 178:1087.
72. National Center for Health Statistics. Vital Statistics of the United States, 1992. Volume 2: Mortality. Part B. Washington, DC: US Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Center for Health Statistics, 1996:180.
73. Haybittle J. Women's risk of dying of heart disease is always greater than their risk of dying of breast cancer [Letter]. Br Med J 1999;318:539.
74. Phillips K-A, Glendon G, Knight JA. Putting the risk of breast cancer in perspective [Editorial]. N Engl J Med 1999;340:141.
75. Schenck-Gustafsson K. Risk factors for cardiovascular disease in women: Assessment and management. Eur Heart J 1996;17(Suppl D):2.
76. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605.
77. Bush TL, Barrett-Connor E, Cowan LD, et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: Results from the Lipid Research Clinics Program Follow-up Study. Circulation 1987; 75:1102.
78. Sullivan JM, Zwaag RV, Hughes JP, et al. Estrogen replacement and coronary artery disease. Effect on survival in postmenopausal women. Arch Intern Med 1990;150:2557.
79. O'Brien JE, Peterson ED, Keeler GP, et al. Relation between estrogen replacement therapy and restenosis after percutaneous coronary interventions. J Am Coll Cardiol 1996;28:1111.
80. Sullivan JM, El-Zeky F, Zwagg RV, Ramanathan KB. Effect on survival of estrogen replacement therapy after coronary artery bypass grafting. Am J Cardiol 1997;79:847.
81. Newton KM, LaCroix AZ, McKnight B, et al. Estrogen replacement therapy and prognosis after first myocardial infarction. Am J Epidemiol 1997;145:269.
82. O'Keefe JHJ, Kim SC, Hall RR, Cochran VC, Lawhorn SL, McCallister BD. Estrogen replacement therapy after coronary angioplasty in women. J Am Coll Cardiol 1997;29:1.
83. Whitehead M, Stampfer M. HERS - A missed opportunity [Editorial]. Climacteric 1998;1:170.
84. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977.
85. Mosca L, Grundy SM, Judelson D, et al. AHA/ACC scientific statement: Consensus Panel statement. Guide to preventive cardiology in women. Circulation 1999; 99:2480.
86. Gaspard UJ, Gottal J-M, van den Brûle FA. Postmenopausal changes of lipid and glucose metabolism: A review of their main aspects. Maturitas 1995;21:171.
87. Godsland IF, Stevenson JC. Postmenopausal hormone replacement therapy and insulin metabolism: Effects of route of administration and implications for heart disease and diabetes risk. Br J Clin Pract 1996;86:1
88. Proudler AJ, Felton CV, Stevenson JC. Ageing and the response of plasma insulin, glucose and C-peptide concentrations to intravenous glucose in postmenopausal women. Clin Sci 1992;83:489.
89. Barrett-Connor E, Ferrara A. Dehydroepiandrosterone, dehydroepiandrosterone sulfate, obesity, waist-hip ratio, and noninsulin-dependent diabetes in postmenopausal women: The Rancho Bernardo Study. J Clin Endocrinol Metab 1996;81:59.
90. Lindheim SR, Presser SC, Ditkoff EC, Vijod MA, Stanczyk FZ, Lobo RA. A possible bimodal effect of estrogen on insulin sensitivity in postmenopausal women and the attenuating effect of added progestin. Fertil Steril 1993;60:664.
91. Crook D, Godsland IF, Hull J, Stevenson JC. Hormone replacement therapy with dydrogesterone and 17β-oestradiol: Effects of serum lipoproteins and glucose tolerance during 24 month follow up. Br J Obstet Gynaecol 1997;104:298.
92. Notelovitz M, Johnston M, Smith S, Kitchens C. Metabolic and hormonal effects of 25-mg and 50-mg 17β-estradiol implants in surgically menopausal women. Obstet Gynecol 1987;70:749.
93. Taylor SI, Accili D, Imai Y. Perspectives in diabetes. Insulin resistance or insulin deficiency: Which is the primary cause of NIDDM? Diabetes 1994;43:735.
94. Cefalu WT, Wang ZQ, Werbel S, et al. Contribution of visceral fat mass to the insulin resistance of aging. Metabolism 1995;44:954.
95. Cefalu WT, Werbel S, Bell-Farrow AD, et al. Insulin resistance and fat patterning with aging: Relationship to metabolic risk factors for cardiovascular disease. Metabolism 1998;47:401.
96. Samaras K, Hayward CS, Sullivan D, Kelly RP, Campbell LV. Effects of postmenopausal hormone replacement therapy on central abdominal fat, glycemic control, lipid metabolism, and vascular factors in type 2 diabetes. Diabetes Care 1999;22:1401.
97. Haffner SM, Valdez RA, Morales PA, Hazuda HP, Stern MP. Decreased sex hormone-binding globulin predicts noninsulin-dependent diabetes mellitus in women but not in men. J Clin Endocrinol Metab 1993;77:56.
98. Lindstedt G, Lundberg P-A, Lapidus L, Lundgren H, Bengtsson C, Bjorntorp P. Low sex hormone-binding globulin concentration as independent risk factor for development of NIDDM. 12-year follow-up of population study of women in Gothenburg, Sweden. Diabetes 1991;40:123.
99. Shoupe D, Lobo RA. The influence of androgens on insulin resistance. Fertil Steril 1984;41:385.
100. Goodman-Gruen D, Barrett-Connor E. Sex hormone-binding globulin and glucose tolerance in postmenopausal women. Diabetes Care 1997;20:645.
101. Andersson B, Marin P, Lissner L, Vermeulen A, Bjorntorp P. Testosterone concentrations in women and men with NIDDM. Diabetes Care 1994;17:405.
102. Moghetti P, Tosi F, Castello R, et al. The insulin resistance in women with hyperandrogenism is partially reversed by antiandrogen treatment: Evidence that androgens impair insulin action in women. J Clin Endocrinol Metab 1996;81:952.
103. Andersson B, Mattsson L-A, Hahn L, et al. Estrogen replacement therapy decreases hyperandrogenicity and improves glucose homeostasis and plasma lipids in postmenopausal women with noninsulin-dependent diabetes mellitus. J Clin Endrocrinol Metab 1997;82:638.
104. Nachtigall LE. Sex hormone-binding globulin and breast cancer risk. Primary Care Update OB/GYNS 1999;6:39.
105. Sowers MR, La Pietra MT. Menopause: Its epidemiology and potential association with chronic diseases. Epidemiol Rev 1995;17:287.
106. Manson JE, Rimm EB, Colditz GA, et al. A prospective study of postmenopausal estrogen therapy and subsequent incidence of non-insulin-dependent diabetes mellitus. Ann Epidemiol 1992;2:665.
107. Gabal LL, Goodman-Gruen D, Barrett-Connor E. The effect of postmenopausal estrogen therapy on the risk of non-insulin-dependent diabetes mellitus. Am J Public Health 1997;87:443.
108. O'Connell MB. Pharmacokinetic and pharmacologic variation between different estrogen products. J Clin Pharmacol 1995;35(Suppl):18S.
109. Ferrara A, Barrett-Connor E, Wingard DL, Edelstein SL. Sex differences in insulin levels in older adults and the effect of body size, estrogen replacement therapy, and glucose tolerance status: The Rancho Bernardo Study, 1984-1987. Diabetes Care 1995;18:220.
110. Bhavnani BR. The saga of the ring B unsaturated equine estrogens. Endocr Rev 1988;9:396.
111. Bhavnani BR, Cecutti A, Dey MS. Biologic effects of delta-8-estrone sulfate in postmenopausal women. J Soc Gynecol Invest 1998;5:156.
112. Brussaard HE, Gevers Leuven JA, Frolich M, Kluft C, Krans HMJ. Short-term oestrogen replacement therapy improves insulin resistance, lipids and fibrinolysis in postmenopausal women with NIDDM. Diabetologia 1997;40:843.
113. Thom M, Chakravarti S, Oram DH, Studd JWW. Effect of hormone replacement therapy on glucose tolerance in postmenopausal women. Br J Obstet Gynaecol 1977;84:776.
114. Kimmerle R, Heinemann L, Heise T, et al. Influence of continuous combined estradiol-norethisterone acetate preparations on insulin sensitivity in postmenopausal nondiabetic women. Menopause 1999; 6:36.
115. Andersson B, Mattsson L-A. The effect of transdermal estrogen replacement therapy on hyperandrogenicity and glucose homeostasis in postmenopausal women with NIDDM. Acta Obstet Gynecol Scand 1999;78:260.
116. Duncan AC, Lyall H, Roberts RN, et al. The effect of estradiol and a combined estradiol/progestagen preparation on insulin sensitivity in healthy postmenopausal women. J Clin Endocrinol Metab 1999; 84:2402.
117. Cucinelli F, Paparella P, Soranna L, et al. Differential effect of transdermal estrogen plus progestagen replacement therapy on insulin metabolism in postmenopausal women: Relation to their insulinemic secretion. Eur J Endocrinol 1999;140:215.
118. Lindheim SR, Duffy DM, Kojima T, Vijod MA, Stanczyk FZ, Lobo RA. The route of administration influences the effect of estrogen on insulin sensitivity in postmenopausal women. Fertil Steril 1994;62: 1176.
119. O'Sullivan AJ, Ho KKY. A comparison of the effects of oral and transdermal estrogen replacement on insulin sensitivity in postmenopausal women. J Clin Endocrinol Metab 1995;80:1783.
120. Cagnacci A, Soldani R, Carriero PL, Paoletti AM, Fioretti P, Melis GB. Effects of low doses of transdermal 17β-estradiol on carbohydrate metabolism in postmenopausal women. J Clin Endocrinol Metab 1992;74:1396.
121. Godsland IF, Gangar K, Walton C, et al. Insulin resistance, secretion, and elimination in postmenopausal women receiving oral or transdermal hormone replacement therapy. Metabolism 1993;42:846.
122. Barrett-Connor E, Laakso M. Ischemic heart disease risk in postmenopausal women: Effects of estrogen use on glucose and insulin levels. Arteriosclerosis 1990;10:531.
123. Spellacy WN, Buhi WC, Birk SA. The effect of estrogens on carbohydrate metabolism: Glucose, insulin, and growth hormone studies on one hundred and seventy-one women ingesting Premarin, mestranol, and ethinyl estradiol for 6 months. Am J Obstet Gynecol 1972;114:378.
124. Ajabor LN, Tsai CC, Vela P, Yen SSC. Effect of exogenous estrogen on carbohydrate metabolism in postmenopausal women. Am J Obstet Gynecol 1972; 113:383.
125. Cefalu WT, Wagner JD, Bell-Farrow AD, et al. The effects of hormonal replacement therapy on insulin sensitivity in surgically postmenopausal cynomolgus monkeys (Macaca fascicularis). Am J Obstet Gynecol 1994;171:440.
126. Wagner JD, Martino MA, Jayo MJ, Anthoney MS, Clarkson TB, Cefalu WT. The effects of hormone replacement therapy on carbohydrate metabolism and cardiovascular risk factors in surgically postmenopausal cynomolgus monkeys. Metabolism 1996;45: 1254.
127. Stevenson JC, Crook D, Godsland IF, Collins P, Whitehead MI. Hormone replacement therapy and the cardiovascular system. Nonlipid effects. Drugs 1994;47(Suppl 2):35.
128. Nabulsi AA, Folsom AR, White A, et al. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med 1993;328:1069.
129. Dunne FP. Should women with diabetes mellitus receive hormone replacement therapy? Int J Clin Pract 1997;51:299.
130. Sargeant LA, Wareham NJ, Khaw KT. Hormone replacement therapy and glucose tolerance in EPIC-Norfolk: A population-based study. Diabetes Metab Res Rev 2000;16:20.
131. Brussaard HE, Gevers Leuven JA, Kluft C, et al. Effect of 17β-estradiol on plasma lipids and LDL oxidation in postmenopausal women with type II diabetes mellitus. Arterioscler Thromb Vasc Biol 1997;17:324.
132. Manwaring P, Morfis L, Diamond T, Howes LG. The effects of hormone replacement therapy on plasma lipids in type II diabetes. Maturitas 2000;34:239.
133. Robinson JG, Folsom AR, Nabulsi AA, Watson R, Brancati FL, Cai J. Can postmenopausal hormone replacement improve plasma lipids in women with diabetes? The Atherosclerosis Risk in Communities Study Investigators. Diabetes Care 1996;19:480.
134. Glueck CJ, Lang J, Hamer T, Tracy T. Severe hypertriglyceridemia and pancreatitis when estrogen replacement therapy is given to hypertriglyceridemic women. J Lab Clin Med 1994;123:59.
135. Kaplan RC, Heckbert SR, Weiss NS, et al. Postmenopausal estrogens and risk of myocardial infarction in diabetic women. Diabetes Care 1998;21:1117.
136. Heckbert SR, Weiss NS, Koepsell TD, et al. Duration of estrogen replacement therapy in relation to the risk of incident myocardial infarction in postmenopausal women. Arch Intern Med 1997;157:1330.
137. Dubuisson JT, Wagenknecht LE,. D'Agostino RB Jr, et al. Association of hormone replacement therapy and carotid wall thickness in women with and without diabetes. Diabetes Care 1998;21:1790.
138. North American Menopause Society. Effects of menopause and estrogen replacement therapy or hormone replacement therapy in women with diabetes mellitus: Consensus opinion of The North American Menopause Society. Menopause 2000;7:87.
139. Luotola H, Pyörälä T, Loikkanen M. Effects of natural oestrogen/progestogen substitution therapy on carbohydrate and lipid metabolism in postmenopausal women. Maturitas 1986;8:245.
140. DeStefano F, Ford ES, Newwman J, et al. Risk factors for coronary heart disease mortality among persons with diabetes. Ann Epidemiol 1993;3:27.
141. Sattar N, McKenzie J, MacCuish AC, Jaap AJ. Hormone replacement therapy in type 2 diabetes mellitus: A cardiovascular perspective [Editorial]. Diabetes Med 1998;15:631.
142. Sattar N, Perera M, Small M, Lumsden M-A. Hormone replacement therapy and sensitive C-reactive protein concentrations in women with type-2 diabetes [Letter]. Lancet 1999;354:487.
143. Hahn L, Mattsson L-Å, Andersson B, Tengborn L. The effects of oestrogen replacement therapy on haemostatic variables in postmenopausal women with non-insulin-dependent diabetes mellitus. Blood Coag Fibrinol 1999;10:81.
144. Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 1998;81:7B.
145. Sattar N, Jaap AJ, MacCuish AC. Hormone replacement therapy and cardiovascular risk in postmenopausal women with NIDDM. Diabetes Med 1996;13: 782.
146. Sattar N, Jaap AJ. Hormone replacement preparations and hypertriglyceridemia in women with NIDDM. Diabetes Care 1997;20:234.